Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 7 Treatment-related adverse events in patients with hepatocellular camrelizumab, n (%)

Variables	BMI < 25 kg/m2 (n = 51)	BMI ≥ 25 kg/m2 (n = 75)	χ2	P value
All grades: Rash	43 (84.31)	56 (74.67)	1.68	0.195
All grades: Nausea	26 (50.98)	30 (40.00)	1.48	0.223
All grades: Diarrhea	13 (25.49)	19 (25.33)	0.00	0.984
All grades: Fatigue	5 (9.80)	20 (26.67)	5.43	0.020
All grades: Myocarditis	3 (5.88)	9 (12.00)	0.70	0.401
All grades: Hyperbilirubinemia	9 (17.65)	10 (13.33)	0.44	0.507
All grades: Hypertension	4 (7.84)	10 (13.33)	0.93	0.336
All grades: Leukopenia	4 (7.84)	10 (13.33)	0.93	0.336
All grades: Thrombocytopenia	7 (13.73)	10 (13.33)	0.00	0.950
All grades: RCCEP	10 (19.61)	11 (14.67)	0.53	0.465
All grades: Neutropenia	4 (7.84)	10 (13.33)	0.93	0.336
All grades: Proteinuria	4 (7.84)	9 (12.00)	0.57	0.451
All grades: Hypothyroidism	5 (9.80)	8 (10.67)	0.02	0.876
All grades: Elevated ALT	6 (11.76)	10 (13.33)	0.07	0.795
All grades: Elevated AST	6 (11.76)	7 (9.33)	0.19	0.660
≥ 3 grades: Rash	5 (9.80)	10 (13.33)	0.36	0.548
≥ 3 grades: Nausea	2 (3.92)	6 (8.00)	0.30	0.583
≥ 3 grades: Diarrhea	0 (0.00)	4 (5.33)	1.34	0.247
≥ 3 grades: Fatigue	3 (5.88)	11 (14.67)	2.37	0.124
≥ 3 grades: Myocarditis	0 (0.00)	3 (4.00)	0.72	0.395
≥ 3 grades: Hyperbilirubinemia	0 (0.00)	3 (4.00)	0.72	0.395
≥ 3 grades: Hypertension	0 (0.00)	1 (1.33)	-	1.000
≥ 3 grades: Leukopenia	0 (0.00)	2 (2.67)	-	0.514
≥ 3 grades: Thrombocytopenia	0 (0.00)	2 (2.67)	-	0.514
≥ 3 grades: RCCEP	1 (1.96)	3 (4.00)	0.02	0.902
≥ 3 grades: Hypothyroidism	1 (1.96)	2 (2.67)	0.00	1.000
≥ 3 grades: Elevated ALT	1 (1.96)	3 (4.00)	0.02	0.902
≥ 3 grades: Elevated AST	3 (5.88)	4 (5.33)	0.00	1.000
≥ 3 grades: Neutropenia	0 (0.00)	0 (0.00)	-	-
≥ 3 grades: Proteinuria	0 (0.00)	0 (0.00)	-	-

BMI: Body mass index; RCCEP: Reactive cutaneous capillary endothelial proliferation; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.